You searched for "diagnostics"

490 results found

Nonacus Clinical Services announce partnership with The London Clinic to deliver GALEAS™ Bladder test

Nonacus Clinical Services, the UK laboratory delivering genomic cancer testing services to the NHS and private healthcare providers, recently announced it is working with The London Clinic to help more patients benefit from its non-invasive GALEAS™ Bladder test for cancer....

Radiation in paediatric urology – PURSE study

Urological operative procedures often use fluoroscopy for diagnosis and treatment of stone disease and structural anomalies. Paediatric tissues are sensitive to the effects of ionising radiation. Paediatric radiation safety has gained concerns due to the possible long-term effects such as...

EAU Patient Information 2019

Credible sources of medical information are difficult to find for patients and healthcare professionals. The European Association of Urologists (EAU) have updated their patient information website since our previous review last year. This digital review focuses on the patient information...

How do we tackle social injustice in urological cancer?

Socioeconomic status as an established determinant of health and associated injustices is well recognised. Confronting these injustices and creating a fairer healthcare system is an ongoing challenge for many governments. In Scotland, the devolved government has created the Scottish Index...

Prostate cancer and an electronic nose

So far the transrectal ultrasound guided (TRUS) biopsy has been the ‘gold standard’ for diagnosing prostate cancer. However, it is invasive and can lead to complications, so there is a need for new non-invasive diagnostic tools to avoid unnecessary biopsy...

The PROMIS trial – time for multi-parametric MRI before a first prostate biopsy

Whilst the relatively random process of 12 core transrectal ultrasound guided (TRUS) prostate biopsy remains by far the most widely employed approach to prostate cancer diagnosis in the UK, its flaws as a standalone diagnostic strategy are increasingly apparent. TRUS-biopsy...

BXTAccelyon becomes global distribution partner for new online prostate MRI self-learning tool to enhance prostate cancer diagnosis

BXTAccelyon, the leading low dose rate (LDR) brachytherapy partner to hospitals and clinics worldwide, and distribution partner for PrecisionPoint™, the...

Challenges of upper tract urothelial carcinoma

Upper tract uroepithelial carcinoma (UTUC) is a fairly common disease which traditionally had poorer outcomes compared to bladder cancer. This is due to various factors leading to delayed diagnosis and problems in risk stratification. Continuing efforts have focused on early...

New ultrasound imaging technique reliably spots prostate cancer, initial patient trial reveals

A groundbreaking new imaging approach developed by researchers at Heriot-Watt University has shown ‘extremely encouraging’ results in early-stage clinical trials on prostate cancer at the Western General Hospital in Edinburgh, Scotland. The ongoing clinical trial demonstrated an initial 94% sensitivity...

Prostate Cancer UK: PSA Consensus Conference 2024

During the conference, you'll get up-to-date information on the latest consensus regarding the PSA blood test. You'll also be able to discuss the diagnostic process for secondary care and learn how to proactively manage conversations about prostate health with patients who are at higher risk. You’ll have plenty of opportunities to ask questions, interact with peers, and apply what you learn through engaging case studies. 9am – 12.30pm

Imaging and surveillance in sporadic renal angiomyolipoma: how and when to monitor effectively

Renal angiomyolipoma (AML) are benign tumours, accounting for approximately 2–3% of all renal neoplasms [1]. Seventy percent of renal AMLs are sporadic, and 20–30% are associated with genetic aetiology. They are composed of smooth muscle, blood vessels, and adipose tissue....

Visual-estimation (cognitive), image-fusion (software) and in-bore targeted prostate biopsy: is there an optimal approach?

The diagnostic superiority of multiparametric magnetic resonance imaging (mpMRI) prior to targeted and systematic prostate biopsy over systematic transrectal ultrasound-guided (TRUS) biopsy alone in the detection of clinically significant prostate cancer (csPCa) has been proven by multiple level 1 studies...